Literature DB >> 23728080

Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.

H A F Stessman1, A Mansoor, F Zhan, S Janz, M A Linden, L B Baughn, B Van Ness.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23728080      PMCID： PMC4053943          DOI： 10.1038/leu.2013.148

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Plasma-cell homing.

Authors:  Eric J Kunkel; Eugene C Butcher
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

2.  Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.

Authors:  Valdas Peceliunas; Ausra Janiulioniene; Reda Matuzeviciene; Tadas Zvirblis; Laimonas Griskevicius
Journal:  Leuk Lymphoma       Date:  2011-12-05

3.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

4.  Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

Authors:  S Z Usmani; J Crowley; A Hoering; A Mitchell; S Waheed; B Nair; Y AlSayed; F Vanrhee; B Barlogie
Journal:  Leukemia       Date:  2012-06-18       Impact factor: 11.528

5.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Authors:  George Mulligan; Constantine Mitsiades; Barb Bryant; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David Schenkein; Dixie-Lee Esseltine; Anthony Boral; Kenneth C Anderson
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

6.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Authors:  John D Shaughnessy; Pingping Qu; Saad Usmani; Christoph J Heuck; Qing Zhang; Yiming Zhou; Erming Tian; Ichiro Hanamura; Frits van Rhee; Elias Anaissie; Joshua Epstein; Bijay Nair; Owen Stephens; Ryan Williams; Sarah Waheed; Yazan Alsayed; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

7.  Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.

Authors:  Makiko Moriuchi; Ken Ohmachi; Minoru Kojima; Kosuke Tsuboi; Yoshiaki Ogawa; Naoya Nakamura; Kiyoshi Ando
Journal:  Tokai J Exp Clin Med       Date:  2010-04-20

8.  Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Authors:  Holly A F Stessman; Linda B Baughn; Aaron Sarver; Tian Xia; Raamesh Deshpande; Aatif Mansoor; Susan A Walsh; John J Sunderland; Nathan G Dolloff; Michael A Linden; Fenghuang Zhan; Siegfried Janz; Chad L Myers; Brian G Van Ness
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

9.  A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authors:  Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

Review 10.  Proteasome inhibitors in the treatment of multiple myeloma.

Authors:  J J Shah; R Z Orlowski
Journal:  Leukemia       Date:  2009-09-10       Impact factor: 11.528
View more
  25 in total

1.  Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.

Authors:  Mathew Weinstock; Yosra Aljawai; Elizabeth A Morgan; Jacob Laubach; Muriel Gannon; Aldo M Roccaro; Cindy Varga; Constantine S Mitsiades; Claudia Paba-Prada; Robert Schlossman; Nikhil Munshi; Kenneth C Anderson; Paul P Richardson; Edie Weller; Irene M Ghobrial
Journal:  Br J Haematol       Date:  2015-04-01       Impact factor: 6.998

Review 2.  Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authors:  Matthew Ho Zhi Guang; Amanda McCann; Giada Bianchi; Li Zhang; Paul Dowling; Despina Bazou; Peter O'Gorman; Kenneth C Anderson
Journal:  Leuk Lymphoma       Date:  2017-06-13

3.  A rare case of IGH/MYC and IGH/BCL2 double hit primary plasma cell leukemia.

Authors:  Anna Kalff; Tiffany Khong; Meaghan Wall; Malgorzata Gorniak; Sridurga Mithraprabhu; Lynda J Campbell; Andrew Spencer
Journal:  Haematologica       Date:  2014-11-07       Impact factor: 9.941

4.  High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.

Authors:  H A F Stessman; A Lulla; T Xia; A Mitra; T Harding; A Mansoor; C L Myers; B G Van Ness; N G Dolloff
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

5.  Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.

Authors:  Tzu-Pei Chang; Vladimir Poltoratsky; Ivana Vancurova
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

6.  Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.

Authors:  Linda B Baughn; Zohar Sachs; Klara E Noble-Orcutt; Amit Mitra; Brian G Van Ness; Michael A Linden
Journal:  Leuk Lymphoma       Date:  2016-12-16

7.  Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

Authors:  Valentina Marchica; Fabrizio Accardi; Paola Storti; Cristina Mancini; Eugenia Martella; Benedetta Dalla Palma; Marina Bolzoni; Katia Todoerti; Magda Marcatti; Chiara Schifano; Sabrina Bonomini; Gabriella Sammarelli; Antonino Neri; Maurilio Ponzoni; Franco Aversa; Nicola Giuliani
Journal:  Int J Hematol       Date:  2016-10-03       Impact factor: 2.490

Review 8.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

9.  Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.

Authors:  Yuhuan Zheng; Qiang Wang; Tianshu Li; Jianfei Qian; Yong Lu; Yi Li; Enguang Bi; Frederic Reu; Yu Qin; Judy Drazba; Eric Hsi; Jing Yang; Zhen Cai; Qing Yi
Journal:  J Natl Cancer Inst       Date:  2016-07-05       Impact factor: 13.506

10.  Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT.

Authors:  Qingqing Pan; Xinxin Cao; Yaping Luo; Jian Li; Jun Feng; Fang Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-27       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.